Skip to search formSkip to main contentSkip to account menu

defactinib

Known as: Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide 
An orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

BenzamidesPyrazinesSulfonamides
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (2)

PF-04554878VS-6063

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BI 853520, a FAK-Simile of Prior FAK Inhibitors?
2018
2018
Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies
Platinum-resistant ovarian cancer (OC) is one of the most lethal gynecological malignancies that has shown minimal improvement in… 
2017
2017
Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
TPS505Background: Focal adhesion kinase (FAK) is consistently hyperactivated in pancreatic ductal adenocarcinoma (PDAC), and FAK… 
2017
2017
INTEGRIN SIGNALING MODULATION DEMONSTRATES POTENTIAL THERAPEUTIC STRATEGY IN BLADDER CANCER USING THREE‐DIMENSIONAL ORGANOID CULTURE: MP48‐09
2015
2015
Abstract 4236: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy
Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung often resulting from prior exposure to… 
2015
2015
FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
Although durable responses to single agent immune checkpoint inhibitors have been reported, additional approaches are needed to… 
2015
2015
Abstract P6-11-06: VS-6063 (defactinib) and VS-4718 reduce cancer stem cells in models of breast cancer: Implications for clinical trials in the neoadjuvant setting
Cancer stem cells (CSCs) are an underlying cause of tumor progression and metastasis. In breast cancer, CSCs can be identified by… 
2014
2014
1601PVS-6063 (DEFACTINIB) TARGETS MESOTHELIOMA CANCER STEM CELLS DIRECTLY AND THROUGH INHIBITION OF TUMOR-ASSOCIATED MACROPHAGES AND CYTOKINE PRODUCTION.
ABSTRACT Aim: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase required for survival of cancer stem cells (CSCs… 
2014
2014
302 FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapy
2013
2013
Abstract A69: Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.
Background: Defactinib (VS-6063) is a potent, reversible, oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK reduces… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)